Product Description
Mechanisms of Action: NPY5 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shionogi
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Obesity|Dyslipidemia|Hypertension|Glucose Intolerance|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-121803 |
JapicCTI-121803 | P2 |
Completed |
Dyslipidemia|Glucose Intolerance|Obesity|Type 2 Diabetes |
2013-05-01 |
|||
JapicCTI-101119 |
JapicCTI-101119 | P2 |
Completed |
Hypertension|Dyslipidemia|Obesity |
2011-03-31 |
|||
NCT01126970 |
1002A2828 | P2 |
Completed |
Obesity |
2011-01-01 |
2019-03-19 |
Treatments |
|
JapicCTI-101111 |
JapicCTI-101111 | P2 |
Completed |
Dyslipidemia|Type 2 Diabetes|Obesity|Glucose Intolerance |
2010-12-31 |
|||
NCT00788528 |
OLE | P2 |
Completed |
Obesity |
2010-02-01 |
2019-03-18 |
Treatments |
|
NCT00748605 |
0702A2824 revised | P2 |
Completed |
Obesity |
2008-11-01 |
2019-03-18 |
Treatments |
|
NCT00747929 |
0701A2823 | P2 |
Completed |
Obesity |
2008-11-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|